NO992336D0 - Raf kinase inhibitors - Google Patents
Raf kinase inhibitorsInfo
- Publication number
- NO992336D0 NO992336D0 NO992336A NO992336A NO992336D0 NO 992336 D0 NO992336 D0 NO 992336D0 NO 992336 A NO992336 A NO 992336A NO 992336 A NO992336 A NO 992336A NO 992336 D0 NO992336 D0 NO 992336D0
- Authority
- NO
- Norway
- Prior art keywords
- kinase inhibitors
- raf kinase
- raf
- inhibitors
- kinase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/56—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9623833.2A GB9623833D0 (en) | 1996-11-16 | 1996-11-16 | Chemical compound |
PCT/GB1997/003102 WO1998022103A1 (en) | 1996-11-16 | 1997-11-12 | Raf kinase inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
NO992336L NO992336L (en) | 1999-05-14 |
NO992336D0 true NO992336D0 (en) | 1999-05-14 |
Family
ID=10803023
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO992336A NO992336D0 (en) | 1996-11-16 | 1999-05-14 | Raf kinase inhibitors |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0941084A1 (en) |
JP (1) | JP2001504478A (en) |
AU (1) | AU4956297A (en) |
CA (1) | CA2267782A1 (en) |
GB (1) | GB9623833D0 (en) |
NO (1) | NO992336D0 (en) |
WO (1) | WO1998022103A1 (en) |
ZA (1) | ZA9710314B (en) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9816837D0 (en) | 1998-08-04 | 1998-09-30 | Zeneca Ltd | Amide derivatives |
US7772432B2 (en) | 1991-09-19 | 2010-08-10 | Astrazeneca Ab | Amidobenzamide derivatives which are useful as cytokine inhibitors |
WO1999015164A1 (en) | 1997-09-23 | 1999-04-01 | Zeneca Limited | Amide derivatives for the treatment of diseases mediated by cytokines |
NZ505844A (en) * | 1997-12-22 | 2003-10-31 | Bayer Ag | Inhibition of raf kinase using substituted heterocyclic ureas |
DE69834842T2 (en) * | 1997-12-22 | 2007-05-10 | Bayer Pharmaceuticals Corp., West Haven | INHIBITION OF RAF-KINASE USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREA |
CN1185211C (en) * | 1998-05-15 | 2005-01-19 | 阿斯特拉曾尼卡有限公司 | Benzamide derivatives for the treatment of diseases mediated by cytokines |
PT1077930E (en) | 1998-05-15 | 2005-03-31 | Astrazeneca Ab | BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES |
US6432949B1 (en) | 1998-08-04 | 2002-08-13 | Astrazeneca Ab | Amide derivatives useful as inhibitors of the production of cytokines |
ATE254105T1 (en) | 1998-09-25 | 2003-11-15 | Astrazeneca Ab | BENZAMIDE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS |
PT1117653E (en) | 1998-10-01 | 2003-06-30 | Astrazeneca Ab | QUINOLINE AND QUINAZOLINE DERIVATIVES AND THEIR USE AS CYTOSINE MEDIUM-INHIBITORS |
AU6513199A (en) | 1998-10-09 | 2000-05-01 | Anadys Pharmaceuticals, Inc. | Aryldiamine derivatives useful as antibacterial agents |
WO2000041698A1 (en) | 1999-01-13 | 2000-07-20 | Bayer Corporation | φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
PT1163237E (en) | 1999-03-17 | 2004-08-31 | Astrazeneca Ab | AMIDA DERIVATIVES |
TR200102568T2 (en) * | 1999-03-17 | 2002-05-21 | Astrazeneca Ab | Amide derivatives. |
GB9906566D0 (en) | 1999-03-23 | 1999-05-19 | Zeneca Ltd | Chemical compounds |
GB9924092D0 (en) | 1999-10-13 | 1999-12-15 | Zeneca Ltd | Pyrimidine derivatives |
AU2002353228B2 (en) * | 2001-12-21 | 2008-09-11 | The Welcome Trust | Genes |
AU2003209116A1 (en) | 2002-02-11 | 2003-09-04 | Bayer Pharmaceuticals Corporation | Aryl ureas with angiogenesis inhibiting activity |
WO2003068746A1 (en) | 2002-02-11 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Aryl ureas as kinase inhibitors |
US7202257B2 (en) | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
US7144911B2 (en) | 2002-12-31 | 2006-12-05 | Deciphera Pharmaceuticals Llc | Anti-inflammatory medicaments |
US7279576B2 (en) | 2002-12-31 | 2007-10-09 | Deciphera Pharmaceuticals, Llc | Anti-cancer medicaments |
WO2004064733A2 (en) * | 2003-01-15 | 2004-08-05 | Board Of Regents, University Of Texas System | The use of c-raf inhibitors for the treatment of neurodegenerative diseases |
DE602004007382T2 (en) | 2003-05-20 | 2008-04-17 | Bayer Pharmaceuticals Corp., West Haven | DIARYL UREAS FOR PDGFR MEDIATED DISEASES |
US7691870B2 (en) | 2003-07-11 | 2010-04-06 | Merck Patent Gmbh | Benzimidazole carboxamides as raf kinase inhibitors |
DE602004010407T2 (en) | 2003-07-23 | 2008-10-16 | Bayer Pharmaceuticals Corp., West Haven | FLUORO-SUBSTITUTED OMEGA-CARBOXYARYLDIPHENYL-UREA FOR THE TREATMENT AND PREVENTION OF DISEASES AND SUFFERING |
GB0324790D0 (en) | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Amide derivatives |
US20060025485A1 (en) * | 2004-07-01 | 2006-02-02 | Kyle Holen | Hydroxybenazamide compounds for treatment of cancer |
CN101010303A (en) * | 2004-09-01 | 2007-08-01 | 阿斯利康(瑞典)有限公司 | Quinazolinone derivatives and their use as B-RAF inhibitors |
AR053992A1 (en) * | 2004-12-22 | 2007-05-30 | Astrazeneca Ab | CHEMICAL COMPOUNDS WITH ANTI-TARGET ACTIVITY, A PROCEDURE FOR THEIR PREPARATION, ITS USE IN THE PREPARATION OF MEDICINES AND PHARMACEUTICAL COMPOSITION. |
JP2008527007A (en) | 2005-01-14 | 2008-07-24 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | Cinnamide and hydrocinnamide derivatives having Raf-kinase inhibitory activity |
US8101610B2 (en) | 2005-11-14 | 2012-01-24 | Genentech, Inc. | Bisamide inhibitors of hedgehog signaling |
JP2010524970A (en) | 2007-04-20 | 2010-07-22 | デシフェラ ファーマシューティカルズ,エルエルシー | Kinase inhibitors useful for the treatment of myeloproliferative disorders and other proliferative disorders |
CN102933560A (en) * | 2010-05-11 | 2013-02-13 | 科瑞塞尼生物科技有限公司 | 4,6-dibenzamido-2-methyl-pyridine derivatives and applications to cancer treatment |
US9198911B2 (en) | 2010-11-02 | 2015-12-01 | The Trustees Of Columbia University In The City Of New York | Methods for treating hair loss disorders |
WO2013149194A1 (en) | 2012-03-29 | 2013-10-03 | The Trustees Of Columbia University In The City Of New York | Methods for treating hair loss disorders |
WO2013032973A1 (en) | 2011-08-29 | 2013-03-07 | Ticona Llc | Aromatic amide compound |
US9045685B2 (en) | 2011-08-29 | 2015-06-02 | Ticona Llc | Cast molded parts formed from a liquid crystalline polymer |
TW201319223A (en) | 2011-08-29 | 2013-05-16 | Ticona Llc | High flow liquid crystalline polymer composition |
WO2013032981A1 (en) | 2011-08-29 | 2013-03-07 | Ticona Llc | High flow liquid crystalline polymer composition |
WO2013032971A1 (en) | 2011-08-29 | 2013-03-07 | Ticona Llc | Melt-extruded substrate for use in thermoformed articles |
TW201319118A (en) | 2011-08-29 | 2013-05-16 | Ticona Llc | Melt polymerization of low melt viscosity liquid crystalline polymers |
WO2013032975A1 (en) | 2011-08-29 | 2013-03-07 | Ticona Llc | Thermotropic liquid crystalline polymer with improved low shear viscosity |
US8906258B2 (en) | 2011-08-29 | 2014-12-09 | Ticona Llc | Heat-resistant liquid crystalline polymer composition having a low melting temperature |
US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
WO2014130275A2 (en) | 2013-02-22 | 2014-08-28 | Ticona Llc | High performance polymer composition with improved flow properties |
WO2015041534A1 (en) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | P90rsk in combination with raf/erk/mek |
US9629851B2 (en) | 2013-09-20 | 2017-04-25 | Stitching Het Nederlands Kanker Institut—Antoni Van Leeuwenhoek Ziekenhuis | ROCK in combination with MAPK pathway |
US20170027940A1 (en) | 2014-04-10 | 2017-02-02 | Stichting Het Nederlands Kanker Instituut | Method for treating cancer |
WO2015178770A1 (en) | 2014-05-19 | 2015-11-26 | Stichting Het Nederlands Kanker Instituut | Compositions for cancer treatment |
TW202122082A (en) | 2019-08-12 | 2021-06-16 | 美商迪賽孚爾製藥有限公司 | Methods of treating gastrointestinal stromal tumors |
CA3150433A1 (en) | 2019-08-12 | 2021-02-18 | Deciphera Pharmaceuticals, Llc | Ripretinib for treating gastrointestinal stromal tumors |
FI4084778T3 (en) | 2019-12-30 | 2023-12-18 | Deciphera Pharmaceuticals Llc | Amorphous kinase inhibitor formulations and methods of use thereof |
CA3163051A1 (en) | 2019-12-30 | 2021-07-08 | Michael D. Kaufman | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2552492A (en) * | 1991-08-23 | 1993-03-16 | United States of America as represented by The Secretary Department of Health and Human Services, The | Raf protein kinase therapeutics |
-
1996
- 1996-11-16 GB GBGB9623833.2A patent/GB9623833D0/en active Pending
-
1997
- 1997-11-12 AU AU49562/97A patent/AU4956297A/en not_active Abandoned
- 1997-11-12 JP JP52331698A patent/JP2001504478A/en active Pending
- 1997-11-12 CA CA002267782A patent/CA2267782A1/en not_active Abandoned
- 1997-11-12 WO PCT/GB1997/003102 patent/WO1998022103A1/en not_active Application Discontinuation
- 1997-11-12 EP EP97912325A patent/EP0941084A1/en not_active Withdrawn
- 1997-11-14 ZA ZA9710314A patent/ZA9710314B/en unknown
-
1999
- 1999-05-14 NO NO992336A patent/NO992336D0/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO1998022103A1 (en) | 1998-05-28 |
ZA9710314B (en) | 1998-05-18 |
CA2267782A1 (en) | 1998-05-28 |
JP2001504478A (en) | 2001-04-03 |
NO992336L (en) | 1999-05-14 |
EP0941084A1 (en) | 1999-09-15 |
GB9623833D0 (en) | 1997-01-08 |
AU4956297A (en) | 1998-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO992336D0 (en) | Raf kinase inhibitors | |
NO20002121D0 (en) | Benzothiazol-protein-tyrosine kinase inhibitors | |
DK1344524T3 (en) | Reflux inhibitors | |
FI963597A0 (en) | Isoprenyylitransferaasi inhibitors | |
NO972930D0 (en) | Fibronectin-adhesion inhibitors | |
ATE236167T1 (en) | P38 INHIBITORS | |
FI972160A (en) | Matriisimetalloproteaasi inhibitors | |
DE69915704D1 (en) | AMPIC DRAM | |
DE69716615D1 (en) | HETEROCYCLIC METALOPROTEAS INHIBITORS | |
ID22982A (en) | SUBSTITUTED PIRAZOLS AS KINASE INHIBITORS p38 | |
CY2007002I2 (en) | O-CARBOXYARYLYPOsubstituted BINYLUREAS AS RAF KINASE INHIBITORS | |
NO974453L (en) | Protein kinase C inhibitors | |
DE69435267D1 (en) | Protein kinase C inhibitors | |
NO984316D0 (en) | Skjμreverkt ° y | |
DK1027332T3 (en) | New lactametalloprotease inhibitors | |
DK0958287T3 (en) | Sulfamidmetalloprotease inhibitors | |
NO983462D0 (en) | Isoleringsverkt ° y | |
PT956294E (en) | TROMBIN INHIBITORS | |
NO990552L (en) | Innrettingsverkt ° y | |
ATE252547T1 (en) | MATRIXMETALLOPROTEINASE INHIBITORS | |
DE29619953U1 (en) | Small transformer | |
PT948483E (en) | FARNESIL-TRANSFERASE INHIBITORS | |
PT986382E (en) | Raf kinase inhibitors | |
KR970059413U (en) | level | |
CY2007006I2 (en) | ALIPOPROTEIN-B INHIBITORS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |